Multi-partner approach for IDRI's leishmaniasis vaccine in India
This article was originally published in Scrip
Executive Summary
Just announced plans to develop and commercialize the Infectious Disease Research Institute's (IDRI) visceral leishmaniasis (VL) vaccine candidate in India are expected to involve a multi-partner approach, with the domestic firms Zydus Cadila and Gennova Biopharmaceuticals working on a potential alliance in the production area.